Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q4 FY25 Earnings Presentation
34 slides from Supriya Lifescience's earnings presentation, May 27, 2025
Slide 1: Cover letter to stock exchanges
May 27, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Presentatio
Slide 2: Investor Presentation | Q4 & FY25
SUPRIYA LIFESCIENCE LTD. Investor Presentation | Q4 & FY25
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Q4 & FY25 Highlights
Q4 & FY25 Highlights
Slide 5: Q4 FY25 Highlights - Regional Performance
Q4 FY25 Highlights Revenue EBITDA PBT PAT Quarterly INR 1841.1 Mn INR 675.8 Mn INR 640.6 Mn INR 503.8 Mn 16% YoY 22% YoY 20% YoY 38% YoY Business Mix Revenue Contribution – By Region Regional Performance 43% 40% 35% 36% 31% 30% 26% Q4 FY24 21% Q3 FY25 11% Q4 FY25 6% 5% 5% 6% 3% 2% Asia Europe LATAM
Slide 6: FY25 Highlights - Regional Performance
FY25 Highlights Revenue EBITDA PBT PAT Yearly INR 6,964.9 Mn INR 2,608.0 Mn INR 2,484.8 Mn INR 1,879.6 Mn 22% YoY 51% YoY 50% YoY 58% YoY Business Mix Revenue Contribution – By Region Regional Performance 41% 38% 37% 33% 22% FY24 11% FY25 6% 4% 5% 3% Asia Europe LATAM North America Others 5 Q4 FY25
Slide 7: Q4 & FY25 - Y-o-Y Highlights
Q4 & FY25 - Y-o-Y Highlights (in INR Mn) Revenue EBITDA PBT PAT +22% +51% +58% +50% 6964.8 2608 1879.6 2484.8 5703.7 +22% +16% +20% 1191.1 1729.8 1656.9 +38% 1581.8 1841.1 555 675.8 640.6 503.8 531.8 364 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25
Slide 8: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Top Therapeutic Areas 49% 42% 15% 13% 11% 11% 8% 7% 7% 5% 4% 3% 3% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive FY24 FY25 7 Q4 FY25 Earnings Presentation
Slide 9: Profit & Loss Statement
Profit & Loss Statement Particulars (in INR Mn) Q4 FY25 Q4 FY24 Y-o-Y Q3 FY25 Q-o-Q FY25 FY24 Y-o-Y Revenue from Operations 1,841.1 1,581.8 16.4% 1,856.5 -0.8% 6,964.8 5,703.4 22.1% Cost of Goods Sold 548.3 582.6 -5.9% 617.8 -11.3% 2,111.8 2,217.4 -4.8% Employee Benefits Expense 209.8 171.4 22.4% 19
Slide 10: Balance Sheet
Balance Sheet (in INR Mn) Assets FY24 FY25 Equity and Liabilities FY24 FY25 Non-current assets Equity (i) Property, plant and equipment 3,037 4,468 (i) Equity share capital 161 161 (ii) Right to Use Asset 48 46 (ii) Other equity 7,993 9,807 (iii)Capital Work in progress 1,488 1,480 Total Equity 8,15
Slide 11: Company Overview
SUPRIYA LIFESCIENCE LTD.
Slide 12: Business Overview
Business Overview Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 33,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GMP, Written Confirmation, IS
Slide 13: Journey So Far
Journey So Far 2020 2021 2022 2023 2024 Third time CEP granted for Pentoxifylline, Esketamine CEP (Certificate of The Company commenced ANVISA Approval USFDA approval Hydrochloride and Salbutamol Sulphate; suitability ) renewed for operations at its Granted NMPA approval granted; Health Canada Pheni
Slide 14: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 18 products are backward integrated* in following the
Slide 15: Diversified Geographic Presence
Diversified Geographic Presence New Therapies Launched • Contrast Media • Cardio Vascular • ADHD Presence in 86+ Countries Across Globe 14 Q4 FY25 Earnings Presentation
Slide 16: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a … with balanced customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 85% 58% 47% 45% 49% 80% 79%
Slide 17: Advanced Manufacturing
Advanced Manufacturing o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, 5 9 warehouse, raw materials, packaging materials and Manufacturing Blocks Clean Rooms finished goods stores o Recently commissioned Effluent
Slide 18: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset DSIR approved facility • A team of 60+ scientists primarily focused on API process development across the value chain 18* 10* DMFs CEPs • Already started two R&D centres – o Ambernath R&D – for formulations and 4* 10* o Lote R&D – Generic APIs & Lifec
Slide 19: CMO Capabilities
CMO Capabilities • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodically trained to enhance skill
Slide 20: Recently Commissioned state-of-the-art E Block
Recently Commissioned state-of-the-art E Block • Capacity: 335 KLPD • Large volume equipment – multipurpose synthesis with focus on backward integration capabilities • Closed systems using gravity flow equipped with process control system. 19 Q4 FY25 Earnings Presentation
Slide 21: FDF Facility ready for commissioning at Ambernath
FDF Facility ready for commissioning at Ambernath • The site spans 5,000 sqm, with 70% of the area constructed, located at Plot No. N-60, Facility Location Additional Ambernath MIDC, District Thane, Maharashtra, • Situated 60 km from Nhava Sheva Port (New Mumbai) and 50 km from Mumbai International
Slide 22: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. High vacuum distillations Simple to highly complex chiral Cyclisation Grignard reaction • molecule
Slide 23: Regulatory Achievements
Regulatory Achievements Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and managing regulatory queries
Slide 24: Regulatory Approvals
Regulatory Approvals USDMF 18 CEP 10 CADIFA Brazil 10 KDMF Korea 5 NMPA China 3 23 Q4 FY25 Earnings Presentation
Slide 25: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 Certificate of Excellence for outstanding Export Special Recognition National Award for Research and Export House for the Year for 2015-16 awarded by Directorate of Performance in the product group Chemicals, Drugs, Development awarded by Ministry of Micro Small
Slide 26: Key Management Team
Key Management Team Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of Supriya Medi-Chem Private Li
Slide 27: EHS
EHS Environment Health Safety • Regular and strict monitoring to produce highest • Clean, safe and healthy working environment for our • Committed to safe and accident-free operations in all efficiency in pollution control all employees our establishments • Safeguarding our employees and facilities
Slide 28: CSR & Social Work
CSR & Social Work We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from the employees to the stude
Slide 29: Historical Financial Performance
Historical Financial Performance
Slide 30: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance (in INR Mn) Robust revenue growth Capex Spend … and, focus on profitability 15.5% 1,623 2,608 1,457 2,140 6,965 1,732 1,880 1,880 949 1,078 1,518 5,301 5,703 1,236 1,289 1,191 3,912 4,609 899 94 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY2
Slide 31: Working Capital Break-up
Working Capital Break-up Inventory Receivables 233 73 206 71 72 198 172 165 63 61 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Payables Net Working Capital 113 112 235 194 196 75 158 59 124 49 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 30 Q4 FY25 Earnings Presentation
Slide 32: Future Outlook
SUPRIYA Outlook cS LIFESCIENCE LTD. 2
Slide 33: Future Outlook
Future Outlook Two new R&D centres CMO/CDMO space • The future of the company is deeply rooted in R&D, with significant progress made to • Company understands large scale special chemical manufacturing and has experience in enhance research capabilities handling hazardous complex process chemistry 1
Slide 34: THANK YOU
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com Ernst & Young LLP Runjhun Jain Sneha Salian +91 98207 20993 +91 98194 30437 runjhun.jain1@in.ey.com sneha2.salian@in.ey.com THANK YOU